Inactive Instrument

Eurofarma Laboratórios S.A. Stock

Equities

EUFA3

BREUFAACNOR4

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Dynamic Chart
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Eurofarma Laboratórios S.A. acquired Genfar S.A. from Sanofi. CI
Abcuro, Inc. announced that it has received $155 million in funding from a group of investors CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Abcuro, Inc. announced that it expects to receive $199.522752 million in funding from Redmile Group, LLC, and other investors CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Eurofarma Laboratórios S.A. agreed to acquire Genfar S.A. from Sanofi for approximately ?300 million. CI
Eurofarma Laboratórios S.A. acquired Laboratório Canonne for BRL 725 million. CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Pfizer Inc. and BioNTech SE Announce Collaboration with Eurofarma Laboratórios SA to Manufacture COVID-19 Vaccine Doses for Latin America CI
Eurofarma Laboratórios S.A. cancelled the acquisition of a portfolio of 12 products in Latin America from Hypera S.A.. CI
More news
Managers TitleAgeSince
Chief Executive Officer - 16-12-31
Chairman - 76-12-31
Investor Relations Contact - 21-11-22
Members of the board TitleAgeSince
Director/Board Member 58 21-11-22
Chairman - 76-12-31
Director/Board Member 75 21-11-22
More insiders
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW